Cargando…
Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2
Due to the COVID-19 pandemic, the rapid development of vaccines against SARS-CoV-2 has been promoted. BNT162b2 is a lipid-nanoparticle mRNA vaccine with 95% efficacy and is the most administered vaccine globally. Nevertheless, little is known about the cellular immune response triggered by vaccinati...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319730/ https://www.ncbi.nlm.nih.gov/pubmed/35891281 http://dx.doi.org/10.3390/vaccines10071117 |
_version_ | 1784755621009031168 |
---|---|
author | Vega-Magaña, Natali Muñoz-Valle, José Francisco Peña-Rodríguez, Marcela Viera-Segura, Oliver Pereira-Suárez, Ana Laura Hernández-Bello, Jorge García-Chagollan, Mariel |
author_facet | Vega-Magaña, Natali Muñoz-Valle, José Francisco Peña-Rodríguez, Marcela Viera-Segura, Oliver Pereira-Suárez, Ana Laura Hernández-Bello, Jorge García-Chagollan, Mariel |
author_sort | Vega-Magaña, Natali |
collection | PubMed |
description | Due to the COVID-19 pandemic, the rapid development of vaccines against SARS-CoV-2 has been promoted. BNT162b2 is a lipid-nanoparticle mRNA vaccine with 95% efficacy and is the most administered vaccine globally. Nevertheless, little is known about the cellular immune response triggered by vaccination and the immune behavior over time. Therefore, we evaluated the T-cell immune response against the SARS-CoV-2 spike protein and neutralization antibodies (nAbs) in naïve and SARS-CoV-2 previously infected subjects vaccinated with BTN162b2. Methods: Forty-six BTN162b2 vaccinated subjects were included (twenty-six naïve and twenty SARS-CoV-2 previously infected subjects vaccinated with BTN162b2). Blood samples were obtained at basal (before vaccination), 15 days after the first dose, and 15 days after the second dose, to evaluate cellular immune response upon PBMC’s stimulation and cytokine levels. The nAbs were determined one and six months after the second dose. Results: SARS-CoV-2 previously infected subjects vaccinated with BTN162b2 showed the highest proportion of nAbs compared to naïve individuals one month after the second dose. However, women were more prone to lose nAbs percentages over time significantly. Furthermore, a diminished CD154+ IFN-γ+ CD4+ T-cell response was observed after the second BTN162b2 dose in those with previous SARS-CoV-2 infection. In contrast, naïve participants showed an overall increased CD8+ IFN-γ+ TNF-α+ T-cell response to the peptide stimulus. Moreover, a significant reduction in IP-10, IFN-λI, and IL-10 cytokine levels was found in both studied groups. Additionally, the median fluorescence intensity (MFI) levels of IL-6, IFNλ-2/3, IFN-𝛽, and GM-CSF (p < 0.05) were significantly reduced over time in the naïve participants. Conclusion: We demonstrate that a previous SARS-CoV-2 infection can also impact cellular T-cell response, nAbs production, and serum cytokine concentration. Therefore, the study of T-cell immune response is essential for vaccination scheme recommendations; future vaccine boost should be carefully addressed as continued stimulation by vaccination might impact the T-cell response. |
format | Online Article Text |
id | pubmed-9319730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93197302022-07-27 Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2 Vega-Magaña, Natali Muñoz-Valle, José Francisco Peña-Rodríguez, Marcela Viera-Segura, Oliver Pereira-Suárez, Ana Laura Hernández-Bello, Jorge García-Chagollan, Mariel Vaccines (Basel) Article Due to the COVID-19 pandemic, the rapid development of vaccines against SARS-CoV-2 has been promoted. BNT162b2 is a lipid-nanoparticle mRNA vaccine with 95% efficacy and is the most administered vaccine globally. Nevertheless, little is known about the cellular immune response triggered by vaccination and the immune behavior over time. Therefore, we evaluated the T-cell immune response against the SARS-CoV-2 spike protein and neutralization antibodies (nAbs) in naïve and SARS-CoV-2 previously infected subjects vaccinated with BTN162b2. Methods: Forty-six BTN162b2 vaccinated subjects were included (twenty-six naïve and twenty SARS-CoV-2 previously infected subjects vaccinated with BTN162b2). Blood samples were obtained at basal (before vaccination), 15 days after the first dose, and 15 days after the second dose, to evaluate cellular immune response upon PBMC’s stimulation and cytokine levels. The nAbs were determined one and six months after the second dose. Results: SARS-CoV-2 previously infected subjects vaccinated with BTN162b2 showed the highest proportion of nAbs compared to naïve individuals one month after the second dose. However, women were more prone to lose nAbs percentages over time significantly. Furthermore, a diminished CD154+ IFN-γ+ CD4+ T-cell response was observed after the second BTN162b2 dose in those with previous SARS-CoV-2 infection. In contrast, naïve participants showed an overall increased CD8+ IFN-γ+ TNF-α+ T-cell response to the peptide stimulus. Moreover, a significant reduction in IP-10, IFN-λI, and IL-10 cytokine levels was found in both studied groups. Additionally, the median fluorescence intensity (MFI) levels of IL-6, IFNλ-2/3, IFN-𝛽, and GM-CSF (p < 0.05) were significantly reduced over time in the naïve participants. Conclusion: We demonstrate that a previous SARS-CoV-2 infection can also impact cellular T-cell response, nAbs production, and serum cytokine concentration. Therefore, the study of T-cell immune response is essential for vaccination scheme recommendations; future vaccine boost should be carefully addressed as continued stimulation by vaccination might impact the T-cell response. MDPI 2022-07-13 /pmc/articles/PMC9319730/ /pubmed/35891281 http://dx.doi.org/10.3390/vaccines10071117 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vega-Magaña, Natali Muñoz-Valle, José Francisco Peña-Rodríguez, Marcela Viera-Segura, Oliver Pereira-Suárez, Ana Laura Hernández-Bello, Jorge García-Chagollan, Mariel Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2 |
title | Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2 |
title_full | Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2 |
title_fullStr | Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2 |
title_full_unstemmed | Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2 |
title_short | Specific T-Cell Immune Response to SARS-CoV-2 Spike Protein over Time in Naïve and SARS-CoV-2 Previously Infected Subjects Vaccinated with BTN162b2 |
title_sort | specific t-cell immune response to sars-cov-2 spike protein over time in naïve and sars-cov-2 previously infected subjects vaccinated with btn162b2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319730/ https://www.ncbi.nlm.nih.gov/pubmed/35891281 http://dx.doi.org/10.3390/vaccines10071117 |
work_keys_str_mv | AT vegamagananatali specifictcellimmuneresponsetosarscov2spikeproteinovertimeinnaiveandsarscov2previouslyinfectedsubjectsvaccinatedwithbtn162b2 AT munozvallejosefrancisco specifictcellimmuneresponsetosarscov2spikeproteinovertimeinnaiveandsarscov2previouslyinfectedsubjectsvaccinatedwithbtn162b2 AT penarodriguezmarcela specifictcellimmuneresponsetosarscov2spikeproteinovertimeinnaiveandsarscov2previouslyinfectedsubjectsvaccinatedwithbtn162b2 AT vieraseguraoliver specifictcellimmuneresponsetosarscov2spikeproteinovertimeinnaiveandsarscov2previouslyinfectedsubjectsvaccinatedwithbtn162b2 AT pereirasuarezanalaura specifictcellimmuneresponsetosarscov2spikeproteinovertimeinnaiveandsarscov2previouslyinfectedsubjectsvaccinatedwithbtn162b2 AT hernandezbellojorge specifictcellimmuneresponsetosarscov2spikeproteinovertimeinnaiveandsarscov2previouslyinfectedsubjectsvaccinatedwithbtn162b2 AT garciachagollanmariel specifictcellimmuneresponsetosarscov2spikeproteinovertimeinnaiveandsarscov2previouslyinfectedsubjectsvaccinatedwithbtn162b2 |